Page 2 - ப்ளூம்பெர்க் கீம்மேல் நிறுவனம் க்கு புற்றுநோய் நோயெதிர்ப்பு சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ளூம்பெர்க் கீம்மேல் நிறுவனம் க்கு புற்றுநோய் நோயெதிர்ப்பு சிகிச்சை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ளூம்பெர்க் கீம்மேல் நிறுவனம் க்கு புற்றுநோய் நோயெதிர்ப்பு சிகிச்சை Today - Breaking & Trending Today

New software package employs deep-learning algorithms to analyze T-cell receptor sequencing data


New software package employs deep-learning algorithms to analyze T-cell receptor sequencing data
Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center have developed DeepTCR, a software package that employs deep-learning algorithms to analyze T-cell receptor (TCR) sequencing data. T-cell receptors are found on the surface of immune T cells. These receptors bind to certain antigens, or proteins, found on abnormal cells, such as cancer cells and cells infected with a virus or bacteria, to guide the T cells to attack and destroy the affected cells.
DeepTCR is an open-source software that can be used to answer questions in research into infectious disease, cancer immunology and autoimmune disease; any place where the immune system has a role through its T-cell receptors, said lead study author John-William Sidhom, an M.D./Ph.D. student at the Johns Hopkins University School of Medicine and Department of Biomedical En ....

United States , John William Sidhom , Emily Henderson , Nature Communications , American Association For Cancer Research , Johns Hopkins Kimmel Cancer Center , Bloomberg Kimmel Institute For Cancer Immunotherapy , Department Of Biomedical Engineering , Johns Hopkins University School Of Medicine , Kimmel Institute , Johns Hopkins University School , Biomedical Engineering , American Association , William Sidhom , Lead Study , Autoimmune Disease , Deep Learning , Immune Response , Immune System , T Cell , ஒன்றுபட்டது மாநிலங்களில் , ஜான் வில்லியம் சீதோம் , எமிலி ஹென்டர்சன் , இயற்கை தகவல்தொடர்புகள் , அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி , ஜான்ஸ் ஹாப்கின்ஸ் கீம்மேல் புற்றுநோய் மையம் ,

Mutant Gene-Targeted Immunotherapy Approach Developed


share:
This news release, issued by Johns Hopkins Medicine, describes a novel targeted immunotherapy approach. This new approach employs bispecific antibodies to treat cancer by eliciting a Tcell response against mutated p53. The researchers used the Highly Automated Macromolecular Crystallography (AMX) and Frontier Microfocusing Macromolecular Crystallography (FMX) beamlines to characterize the molecular structure of the proteins. AMX and FMX are beamlines at the National Synchrotron Light Source II (NSLS-II) a U.S. Department of Energy (DOE) Office of Science User Facility at Brookhaven National Laboratory. NSLS-II offers a comprehensive suite of life science research capabilities. Johns Hopkins media contacts: Amy Mone, 410-614-2915, amone@jhmi.edu, or Valerie Mehl, 410-614-2916, mehlva@jhmi.edu. Brookhaven Lab media contacts: Cara Laasch, 631-344-8458, laasch@bnl.gov or Peter Genzer, 631-344-3174, genzer@bnl.gov. ....

United States , Michaelb Murphy , Shibin Zhou , Valerie Mehl , Emily Han , Nickolas Papadopoulos , Michael Hwang , Evangeline Watson , Katharine Wright , Astra Zeneca Medimmune Amplimmune , Katharinem Wright , Yana Li , Elizabeth Cook , Patricka Brown , Gabriel Ghiaur , Bristol Myers Squibb , Bert Vogelstein , Kenneth Kinzler , Suman Paul , P Aitana Azurmendi , Sandra Gabelli , Chetan Bettegowda , Chung Hsiue , Michelles Miller , Andrew Skora , Sarahr Dinapoli ,

New cancer immunotherapy uses engineered T cells to target a common genetic alteration


New cancer immunotherapy uses engineered T cells to target a common genetic alteration
Researchers developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers. The approach, which stimulates an immune response against cells that are missing one gene copy, called loss of heterozygosity (LOH), was developed by researchers at the Ludwig Center, Lustgarten Laboratory and the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center.
Genes have two alleles, or copies, with one copy inherited from each parent. Cancer-related genetic alterations commonly involve the loss of one of these gene copies. ....

Kenneth Kinzler , Shibin Zhou , Michael Hwang , Bert Vogelstein , Emily Henderson , Ludwig Center , Bloomberg Kimmel Institute For Cancer Immunotherapy , Johns Hopkins Kimmel Cancer Center , Proceedings Of The National Academy Sciences , Johns Hopkins University School Of Medicine , Lustgarten Laboratory , Kimmel Institute , Johns Hopkins Kimmel Cancer , National Academy , Johns Hopkins University School , Brian Mog , Immune Response , ஷிபின் ஜூ , மைக்கேல் ஹ்வ்யாஂக் , பெர்ட் வோகல்ஸ்டீன் , எமிலி ஹென்டர்சன் , லுட்விக் மையம் , ப்ளூம்பெர்க் கீம்மேல் நிறுவனம் க்கு புற்றுநோய் நோயெதிர்ப்பு சிகிச்சை , ஜான்ஸ் ஹாப்கின்ஸ் கீம்மேல் புற்றுநோய் மையம் , ஜான்ஸ் ஹாப்கின்ஸ் பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து , கீம்மேல் நிறுவனம் ,

Cancer immunotherapy approach targets common genetic alteration


 E-Mail
IMAGE: Novel cancer immunotherapy approach inverts a missing gene copy into an immune cell-activating signal.
view more 
Credit: Elizabeth Cook
Researchers developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers. The approach, which stimulates an immune response against cells that are missing one gene copy, called loss of heterozygosity (LOH), was developed by researchers at the Ludwig Center, Lustgarten Laboratory and the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center.
Genes have two alleles, or copies, with one copy inherited from each parent. Cancer-related genetic alterations commonly involve the loss of one of these gene copies. ....

United States , Shibin Zhou , Emily Han , Nickolas Papadopoulos , Michael Hwang , Astrazeneca Medimmune Amplimmune , Jacqueline Douglass , Johns Hopkins , Alexander Pearlman , Sarah Dinapoli , Bert Vogelstein , Kenneth Kinzler , Suman Paul , Sandra Gabelli , Chetan Bettegowda , Maximilian Konig , Chung Hsiue , Johns Hopkins University , Commonwealth Fund , Bloomberg Kimmel Institute For Cancer Immunotherapy , Dk Ludwig Fund For Cancer Research , Johns Hopkins Kimmel Cancer Center , Bristol Myers Squibb , National Cancer Institute Grant , Dracen Pharmaceuticals , National Institutes Of Health ,